HSBC Holdings plc Increases AstraZeneca plc (LON:AZN) Price Target to GBX 4,340

AstraZeneca plc (LON:AZN) had its price target increased by HSBC Holdings plc from GBX 4,150 ($54.58) to GBX 4,340 ($57.08) in a research report released on Wednesday, November 1st. They currently have a reduce rating on the biopharmaceutical company’s stock.

AZN has been the topic of several other research reports. Liberum Capital restated a buy rating and set a GBX 4,800 ($63.13) price target on shares of AstraZeneca plc in a report on Tuesday, September 5th. UBS AG set a GBX 4,550 ($59.84) price objective on AstraZeneca plc and gave the company a neutral rating in a research report on Monday, October 23rd. Jefferies Group LLC upped their price objective on AstraZeneca plc from GBX 4,350 ($57.21) to GBX 4,800 ($63.13) and gave the company a hold rating in a research report on Monday, September 11th. Deutsche Bank AG reaffirmed a buy rating and issued a GBX 5,600 ($73.66) price objective on shares of AstraZeneca plc in a research report on Wednesday, October 11th. Finally, Shore Capital reissued a hold rating on shares of AstraZeneca plc in a research report on Tuesday, August 29th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of GBX 5,247.18 ($69.01).

Shares of AstraZeneca plc (LON AZN) traded up GBX 57.50 ($0.76) on Wednesday, hitting GBX 4,927.50 ($64.81). The stock had a trading volume of 1,037,352 shares, compared to its average volume of 1,940,000. AstraZeneca plc has a twelve month low of GBX 3,996 ($52.56) and a twelve month high of GBX 5,520 ($72.60).

ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://ledgergazette.com/2017/11/13/hsbc-holdings-plc-boosts-astrazeneca-plc-azn-price-target-to-gbx-4340.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply